Recent research indicates that semaglutide, the active ingredient in Ozempic and Wegovy, may significantly reduce alcohol consumption in individuals with alcohol use disorder (AUD). A study published in JAMA Psychiatry involved 48 participants diagnosed with AUD. Over a nine-week period, those administered semaglutide reported a 30% reduction in alcohol intake and experienced fewer cravings compared to the placebo group.
Semaglutide, originally developed for type 2 diabetes and later approved for weight management, functions as a GLP-1 receptor agonist. It influences the brain’s reward system, potentially diminishing the dopamine-driven urges associated with addictive behaviors. This mechanism may explain the observed decrease in alcohol and cigarette consumption among study participants.
These findings suggest that GLP-1 receptor agonists like semaglutide could offer a novel approach to treating substance use disorders. However, experts emphasize the necessity for larger, long-term studies to fully understand the drug’s efficacy and safety in this context. Until more comprehensive data is available, healthcare providers advise caution and do not recommend using semaglutide for addiction treatment outside of clinical trials.
The potential repurposing of semaglutide for AUD treatment could have significant public health implications, offering a new therapeutic avenue for individuals struggling with alcohol dependence. As research progresses, it will be crucial to balance the benefits against any risks and to consider individual patient needs in clinical decision-making.
Semaglutide Shows Promise in Reducing Alcohol Consumption
The TimesWeight-loss jabs can cut alcohol use by 40%7 days agoTimeWeight-Loss Drugs Like Ozempic Can Help Alcohol Addiction7 days ago
Sources